TCBP - TC Biopharm surges 18% on strategic collaboration to advance gamma delta T cells for oncology

• TC Biopharm ( NASDAQ: TCBP ) is trading 18.5% higher premarket after it announced a strategic collaboration with The University of Texas MD Anderson Cancer Center to test on how gamma-delta T cells work in oncology settings.
• Under the collaboration, MD Anderson's clinical trial infrastructure and research expertise will help TC BioPharm's targeted gamma-delta T cell oncology pipeline.
• Under the terms of the three-year agreement, the research teams will work together on both preclinical and clinical studies to evaluate the potential for gamma-delta T cell therapies and to better understand the behaviors of these cells in patients.
• The immunoprofiling capabilities of MD Anderson's immunotherapy platform will help correlative studies on clinical samples to uncover detailed insights on the behavior of gamma-delta T cells and corresponding responses in patients.

For further details see: